New test measures lupus brain fog, filling gap in patient care
Researchers have created the first validated scale to measure cognitive symptoms—'brain fog'—in lupus patients, a common but previously unmeasurable complaint. The tool could help clinicians track treatment effectiveness and improve outcomes for the estimated 1.5 million lupus patients worldwide who experience debilitating mental fog.
Originaltitel: International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study.
Lupus Brain Fog Severity Scale (LBFSS) är det första patientrapporterade mätinstrumentet för kognitiva symptom hos SLE-patienter och öppnar vägen för standardiserad klinisk värdering av hjärnmist – ett vanligt men dittills omätt problem i reumatisk vård. Forskare från 36 länder validerade skalan på 378 patienter. LBFSS uppvisade hög intern konsistens (Cronbach's α=0,95), ett enhetligt mätförhållande och löste 62,2 procent av variansen i kognitiva symtom. Instrumentet skiljer väl mellan patienter med och utan självrapporterad hjärnmist (AUC=0,85) och korrelerar starkt med funktionell påverkan och symptomsvårlighet. För regionvård och MedTech-aktörer är detta relevant då en validerad PROM möjliggör evidensbaserad uppföljning av behandlingseffekt, förbättrar patientselektionen i kliniska försök och skapar behov av integrerad screening-infrastruktur i reumatologisk vård.
INTRODUCTION: Cognitive symptoms such as 'brain fog' are frequent and disabling in patients with SLE. We aimed to develop and validate the Lupus Brain Fog Severity Scale (LBFSS), the first patient-reported outcome measure (PROM) for cognitive symptoms in SLE. METHODS: The LBFSS was developed using a multi-step international approach involving healthcare professionals and patients with SLE. Patients provided free-text descriptions of brain fog, generating candidate domains through thematic analysis (step 1). Domains were rated for relevance (step 2) and those retained converted into self-assessable items (step 3). The pilot LBFSS was iteratively refined (step 4). The finalised LBFSS was validated (step 5) in a large international SLE cohort. Psychometric evaluation included internal consistency, exploratory factor analysis and assessment of construct, convergent, known-groups and criterion-related validity. RESULTS: In step 1, 147 SLE participants across 39 countries generated 21 domains for cognitive symptoms, of which 13 were retained in consensus (step 2), converted into self-assessable items (step 3) and iteratively refined using patient and physician feedback. In step 5, validation of the LBFSS instrument in 378 patients from 36 countries demonstrated high internal consistency (Cronbach's α=0.95) and a unidimensional structure explaining 62.2% of variance. LBFSS scores were significantly higher in participants reporting brain fog (p<0.0001), confirming known-group validity. Construct validity was supported by significant correlations with functional impact and symptom severity (ρ=0.46-0.65, p<0.0001), strong convergent validity with the Perceived Deficits Questionnaire-20 (ρ=0.84, p<0.0001) while the discriminative performance for presence versus absence of self-reported brain fog was high (area under the curve=0.85). CONCLUSION: The LBFSS is a new, valid and feasible PROM to assess brain fog and cognitive symptoms in SLE.